FDA grants Breakthrough Therapy designation to Glycomine’s GLM101 for PMM2-CDG treatment

• Glycomine won FDA Breakthrough Therapy designation for GLM101 in PMM2-CDG, a rare multisystem disorder with no approved treatments.
• Decision followed Phase 2a data showing improvements in ataxia and other clinical measures after 24 weeks of treatment.
• GLM101 is an investigational liposomal mannose-1-phosphate substrate replacement therapy targeting the underlying glycosylation defect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pappas Capital LLC published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.